Olink^® services

In 2024, Rules-Based Medicine (RBM) added the Olink Target platform. Olink Target uses Proximity Extension Assay (PEA) technology combined with quantitative PCR readout to deliver optimal specificity and data quality while still delivering a scalable, high-throughput solution.

RBM currently offers the Target 48 Cytokine panel, with additional offerings planned. These cytokines are associated with inflammation and immune system regulation, demonstrating utility across several therapeutic research areas, including autoimmune, oncology, immuno-oncology, neurology, and cardiovascular disease.

The addition of Olink expands RBM’s ability to support customers in understanding complex mechanisms of action throughout the development pipeline from therapeutic area-based discovery to custom Flex or Focus panels.

Review our bibliography to see how our assays have supported hundreds of peer-reviewed papers.